Valeant Pharmaceuticals will pay about $1 billion to buy Sprout Pharmaceuticals, the maker of the first prescription drug designed to boost sexual desire in women. Thursday's deal comes one day after regulators approved the pill. Valeant expects the Sprout pill, Addyi, to be available in the United States in the fourth quarter. The deal to buy the company should close in this quarter. The Canadian drugmaker will pay about $500 million at closing for Sprout and then make another milestone-based payment of around $500 million in the first quarter of next year.
Keep up to date with what’s happening in Turkey,
it’s region and the world.
You can unsubscribe at any time. By signing up you are agreeing to our Terms of Use and Privacy Policy.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
